TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-1943
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-Resistant Prostate Cancer After Chemotherapy

Klinicka Onkologie
Oncology
2016English

Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients

European urology oncology
OncologyRadiologyUrologyNuclear MedicineImagingSurgery
2019English

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide

Clinical Medicine Insights: Oncology
Oncology
2013English

Radiotherapy in Metastatic Castration Resistant Prostate Cancer Patients With Oligo-Progression During Abiraterone-Enzalutamide Treatment: A Mono-Institutional Experience

Radiation Oncology
Nuclear MedicineRadiologyImagingOncology
2019English

Abiraterone in Metastatic Castration-Resistant Prostate Cancer: Efficacy and Safety in Unselected Patients

Cancer Treatment and Research Communications
Cancer ResearchOncology
2018English

Mp52-11 Association of Dose Reduction of Abiraterone Acetate Plus Prednisone or Enzalutamide and Psa Progression in Veterans With Metastatic Castration Resistant Prostate Cancer

Journal of Urology
Urology
2018English

Pharmacoeconomic Evaluation of Enzalutamide, Abiraterone and Cabazitaxel for the Treatment of Post-Chemotherapy Patients With Metastatic Castration-Resistant Prostate Cancer

Medical Technologies. Assessment and Choice (Медицинские технологии. Оценка и выбор)
2018English

Mechanisms of Acquired Resistance to Androgen Receptor Targeting Drugs in Castration-Resistant Prostate Cancer

Expert Review of Anticancer Therapy
OncologyPharmacology
2014English

Collateral Resistance to Taxanes in Enzalutamide-Resistant Prostate Cancer Through Aberrant Androgen Receptor and Its Variants

Cancer Science
Cancer ResearchMedicineOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy